AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$AZTA

Why Azenta Stock Crushed it on Wednesday

Azenta (AZTA) stock surged 21% after reporting Q4 2026 revenue of $167M, up 5% YoY, and adjusted earnings of $0.28 per share, exceeding estimates. The company guided FY2027 revenue to $648M-$660M with margin expansion. Azenta focuses on automated sample storage for healthcare.

Original reporting
finance.yahoo.com
Published Nov 12, 2026, 1:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 2:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Why Azenta Stock Crushed it on Wednesday — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AZTABullishHigh
01

Why it matters

Earnings beat and guidance above consensus suggest near‑term price appreciation.

02

Market read

The earnings surprise and strong guidance make AZTA a near‑term buying opportunity.

03

What to watch

Flat multiomics segment and macro‑economic headwinds could limit growth.

Relevance 7/10Novelty 8/10Timing: today

Background

Azenta (NASDAQ:AZTA) focuses on automated sample storage for healthcare, reporting Q4 2026 results and 2027 outlook.

Company-level read

Ticker impact

$AZTABullishHigh confidence
Context

Azenta reported Q4 2026 results with revenue up 5% YoY to $167M and beat earnings expectations, plus issued 2027 guidance that tops consensus.

Expected impact

upward pressure as the market prices in the earnings beat and higher guidance

Evidence & confidence

Revenue and EPS both exceeded estimates and guidance is above consensus, driving bullish sentiment.

Market effects

Sector

Positive for healthcare technology and sample storage niche, may lift peers.

Regional

U.S. market, especially biotech/healthcare tech segment.

Global

Limited to investors tracking US-listed health‑tech stocks.

Counterpoint

What could challenge this read

Guidance still leaves upside potential; execution risk could temper gains.

Key entities

  • company
    Azenta

    Healthcare technology firm providing sample storage solutions.

Read at source← All news

StoryAzenta reports Q4 2026 earnings beat and raises FY 2027 revenue outlook

Also covered by

6 outlets

Related articles

$AZTAHigh

Azenta (AZTA) Q4 2026 Earnings Call Transcript

Azenta (AZTA) reported Q4 2026 revenue slightly better than expected, with double-digit growth in Sample Repository Services and Consumables & Instruments. The company aims for profitable revenue growth in 2027, with initiatives in commercial expansion and new product launches. Fiscal 2026 saw 2% organic revenue growth and an adjusted EBITDA margin of 9.4%.

finance.yahoo.com
$AZTAMedAI 8/10

What Azenta (AZTA) Said on Its Q4 Earnings Call

Azenta (AZTA) reported Q4 revenue growth of 9% in Sample Management Solutions and flat revenue in Multiomics. The company expects 3-4% organic revenue growth in Q1 and improved free cash flow by 25% in fiscal 2026. Automated Stores faced challenges but is expected to return to modest growth. Azenta made acquisitions in gene synthesis and plans restructuring for cost savings.

finance.yahoo.com